Press releases

Press release
MIV-247 has been selected as a candidate drug and enters development for the treatment of neuropathic pain

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that MIV-247 has been selected as a candidate drug (CD) from its cathepsin S...

Read more
Press release
Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced further results from the phase I clinical study on the investigational cathepsin K inhibitor...

Read more
Press release
Janssen has acquired an NS5a replication complex inhibitor that will be evaluated with Simeprevir in future clinical development

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an...

Read more
Press release
Simeprevir data from COSMOS study in Hepatitis C patients will be presented as late-breaking presentation at AASLD

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir...

Read more
Press release
Medivir announces that Simeprevir data will be presented at the upcoming AASLD meeting

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data will be presented on the investigational protease inhibitor simeprevir for the...

Read more
Press release
Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection

Stockholm, Sweden — Medivir AB (OMX: MVIR) today reports that Janssen Pharmaceutical R&D Ireland (Janssen) has been informed by the Japanese...

Read more
Press release
Medivir Capital Markets Day on 10 October 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that a Capital Markets Day will be arranged for journalists, analysts and...

Read more
Press release
Ferrer and Medivir enter agreement for commercializing a new treatment for agitation associated with schizophrenia and bipolar disease in the Nordics

Under the terms of the agreement, Ferrer grants to Medivir the exclusive rights to promote, market, sell and distribute ADASUVE in...

Read more
Press release
The regulatory process in Japan for simeprevir

Stockholm, Sweden — Medivir AB (OMX: MVIR) On February 22, 2013 Janssen submitted a regulatory application to the Japanese Ministry of...

Read more
Press release
The collaboration with Daewoong Pharmaceutical for the development of the hepatitis B compound, MIV-210 has been discontinued

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that it has discontinued the development of its hepatitis B compound MIV-210...

Read more
Press release
Medivir announces interim results from Cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3-F4

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced interim results from the second Cohort in the ongoing COSMOS study evaluating...

Read more
Press release
Interim Report, 1 January – 30 June 2013*

Q2 2013 (April – June) Remaining Group operations, excluding Cross Pharma Net turnover totalled SEK 40.7 million (SEK 39.0 m). The...

Read more